DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: leuprolide (Drug); letrozole (Drug); zoledronic acid (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Dana-Farber Cancer Institute

Official(s) and/or principal investigator(s):
Ann Partridge, MD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute


The purpose of this study is to determine the safety and tolerability of the combination of two drugs (letrozole and leuprolide) in women who have already taken tamoxifen for at least 4. 5 years. Letrozole, an aromatase inhibitor (which blocks an enzyme that produces estrogen), is a drug that is FDA approved. It has been shown to reduce the risk of breast cancer recurrence in postmenopausal women with breast cancer who have been previously treated with tamoxifen. Letrozole works by stopping the production of estrogen in parts of the body other than the ovaries. Leuprolide is a drug that stops a women's ovarian cycles. This process is known as ovarian function suppression. Stopping a women's menstrual cycle may be effective against breast cancer for some patients when given as initial therapy. The combination of letrozole and leuprolide is considered a standard treatment for women with metastatic breast cancer, and is also sometimes used for treatment of premenopausal early stage breast cancer, but it has not been accepted as a standard of care treatment.

Clinical Details

Official title: Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To determine the tolerability at one year of ovarian function suppression (OFS) using leuprolide and letrozole in this patient population.

Secondary outcome:

To explore the effect of ovarian function suppression (OFS) combined with aromatase inhibition combined with intravenous bisphosphonate therapy on bone mineral density in this patient population.

To evaluate the effect of OFS combined with aromatase inhibitor therapy on the incidence and severity of menopausal symptoms, sexual dysfunction, musculoskeletal complaints, other side effects and overall quality of life in this population.

Detailed description:

- Participants will be given a monthly intramuscular injection of leuprolide. Six to

eight weeks after the first leuprolide injection, participants will be instructed to begin taking letrozole pills by mouth at home each day.

- During this research study, participants will also be offered injections of zoledronic

acid to preserve bone mineral density. If desire, these injections will be given every 6 months for a total of 4 injections during the course of the research study.

- The treatments in this research study may increase the risk of bone density loss, so

vitamin D and calcium supplements will be recommended to participants.

- The following tests and procedures will be performed during the research study:

Physical Exam (every visit); Blood tests; Urine test (beginning and end of treatment); Imaging (annual mammograms); Bone Density (DXA) Scan (beginning and end of treatment); Questionnaires (throughout the study).

- Participants will be on this study for about two years.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Women 18 years of age or older

- History of invasive ER+ or PR+ breast cancer treated with at least 4. 5 years of


- No current evidence of recurrent invasive disease or metastatic disease. Patients

may have a history of bilateral breast cancer

- Premenopausal (estradiol level in premenopausal range, >20pg/ml, within the prior 28


- Liver function tests and creatinine <2. 5 times the upper limit of normal within the

28 days prior to enrollment

- ECOG Performance Status 0-1

- Must agree to use non-hormonal contraception (condoms, diaphragm, IUD, sterilization,

abstinence, etc) and no other hormonal therapy during trial and until 3 months after letrozole is stopped

- Negative pregnancy test within 14 days prior to enrollment

- Patient must be able to speak, read and write in English

Exclusion Criteria:

- Previous treatment with an oral or IV bisphosphonate in the prior two years

- History of cancer other than breast cancer within 5 years excluding basal/squamous

cell skin carcinoma in situ of the cervix

- Women with evidence of current local recurrence or metastatic breast cancer

- Pregnant women

- Nursing women

- Women who are currently taking tamoxifen and are unwilling to stop this medication

- Women with a known deleterious BRCA 1 or BRCA 2 mutation

Locations and Contacts

University of Colorado, Denver, Colorado 80217, United States

Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, United States

Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

Newton Wellesley Hospital, Newton, Massachusetts 02462, United States

Additional Information

Starting date: May 2009
Last updated: March 6, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017